Loading
Life sciences · Journal article
Journal of Personalized Medicine · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Stereotactic body radiation therapy (SBRT), often delivered in 3–5 fractions, is a highly effective treatment strategy for early-stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Biology-guided radiotherapy (BGRT), a PET-guided SBRT, enables acquisition of patient-specific metabolic, anatomical, and dose information at each fraction. While prior models have focused on static, population-level prediction of radiation-induced toxicity, there remains a lack of approaches to characterize how normal tissue response evolves longitudinally within individual patients over the course of radiation treatment. We therefore hypothesize that AI-based models can quantify temporal toxicity patterns in such longitudinal data, allowing clinicians to balance tumor control against normal tissue complications to guide individualized treatment planning. Methods: In this proof-of-concept study, we developed COMPASS (COMprehensive Personalized Assessment System), a digital twin framework that generates per-fraction risk estimates that could inform future adaptive decision-making in NSCLC. With Yale Institutional Review Board approval, eight patients with NSCLC who underwent BGRT were retrospectively included in this study. A total of 99 organ–fraction observations, spanning 24 patient–organ longitudinal trajectories across three organs-at-risk (spinal cord, heart, and esophagus), were used to train a Gated Recurrent Unit (GRU) autoencoder to learn latent temporal representations, which were subsequently characterized using logistic regression to assess for CTCAE ≥ 1 toxicity. Results: In a leave-one-out patient evaluation, COMPASS achieved an area under the curve (AUC) of 0.90, with 80% sensitivity and 78.6% specificity in predicting normal tissue toxicity at the patient–organ trajectory level on a fractional basis. Conclusions: These findings support the feasibility of AI-driven digital twins for per-fraction toxicity monitoring, offering a step toward personalized radiotherapy for NSCLC patients.